Business
TransCode Therapeutics Announces 1-for-28 Reverse Stock Split
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for c
About this update from Transcode Therapeutics, Inc.
[{"type":"text","content":"Split designed to achieve compliance with Nasdaq minimum bid price requirements","length":79,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.","length":610,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/TransCode Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":58,"url":"https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y2kxVj5Zztrmutz6upX.Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/6158e3f623b2cdcf70a213bfe6b5eb12","width":400,"height":58}},"href":"https://mma.prnewswire.com/media/2583692/TransCode_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The 1-for-28 reverse stock split will automatically convert twenty-eight current shares of TransCode's common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. In lieu of issuing fractional shares, stockholders of record who otherwise would be entitled to receive fractional shares will be entitled to rounding up of the fractional share to the nearest whole number. The reverse split will reduce the number of shares of common stock outstanding from 23,341,336 shares to approximately 833,620 shares. Proportional adjustments also will be made to the exercise prices of TransCode's outstanding stock options and warrants, and to the number of shares issued and issuable under TransCode's stock incentive plans.","length":795,"tagName":"p"},{"type":"text","content":"Vstock Transfer LLC will act as the ...